Climb Bio, Inc. (NASDAQ: CLYM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
12.56
+0.75+6.35%
Analyst
Up 6.4% — RBC Capital initiated coverage at Outperform, price target $23.
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 38.26% | Shs Outstand | 68.18M | Perf Week | 2.20% |
| Market Cap | 856.40M | Forward P/E | - | EPS next Y | -1.05 | Insider Trans | -0.69% | Shs Float | 59.86M | Perf Month | -5.35% |
| Enterprise Value | 755.40M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 11.48% | Perf Quarter | 29.62% |
| Income | -60.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 5.70 | Perf Half Y | 165.54% |
| Sales | 0.00 | P/B | 5.35 | EPS next Y | -20.07% | ROA | -34.65% | Short Interest | 6.87M | Perf YTD | 214.00% |
| Book/sh | 2.35 | P/C | 8.48 | EPS next 5Y | - | ROE | -31.46% | 52W High | 14.42 -12.90% | Perf Year | 766.21% |
| Cash/sh | 1.48 | P/FCF | - | EPS past 3/5Y | - | ROIC | -40.44% | 52W Low | 1.54 715.58% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.90% 7.53% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 49.02% | Oper. Margin | 0.00% | ATR (14) | 0.97 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 27.86 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 51.03 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 27.86 | EPS Q/Q | 35.48% | SMA20 | -1.89% | Beta | 2.02 | Target Price | 21.80 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | 2.97% | Rel Volume | 0.84 | Prev Close | 11.81 |
| Employees | 29 | LT Debt/Eq | - | Earnings | Aug 11 | SMA200 | 75.17% | Avg Volume | 1.23M | Price | 12.56 |
| IPO Date | Aug 10, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 30.54% - | Net Debt/EBITDA | 0.15 | Volume | 1,031,570 | Change | 6.35% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-03-26 | Initiated | RBC Capital | Outperform | $23 |
| Jun-11-26 | Reiterated | BTIG | Buy | $20 |
| Jun-08-26 | Initiated | Guggenheim | Buy | $35 |
| Jun-08-26 | Reiterated | BTIG | Buy | $20 |
| May-12-26 | Reiterated | HC Wainwright & Co. | Buy | $11 → $20 |
| May-08-26 | Reiterated | Wedbush | Outperform | $17 |
| May-06-26 | Reiterated | Robert W. Baird | $12 → $21 | |
| May-05-26 | Initiated | Chardan | Buy | $22 |
| Apr-15-26 | Initiated | Mizuho | Outperform | $18 |
| Mar-17-26 | Reiterated | Truist Financial | $17 |
Latest News
Jul-28-26
01:21AM
Jul-27-26
Jul-23-26
Jul-23-2612:27PM
Jun-24-26
Jun-12-26
10:19AM
Jun-11-26
Company
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 21 | 16 | 25 | 19 | 12 | 2 | 1 | |
| Research and Development | 47 | 14 | 15 | 26 | 23 | 9 | 4 | |
| Other Operating Expense | 0 | 52 | 0 | 0 | 1 | 10 | 2 | |
| Operating Income | -68 | -82 | -40 | -45 | -36 | -21 | -7 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 8 | 5 | 0 | -12 | 0 | 1 | |
| Net Income Before Taxes | -60 | -74 | -35 | -45 | -47 | -21 | -7 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -60 | -74 | -35 | -45 | -47 | -21 | -7 | |
| Net Income From Continuing Operations | -60 | -74 | -35 | -45 | -47 | -21 | -7 | |
| Net Income | -60 | -74 | -35 | -45 | -47 | -21 | -7 | |
| EPS (Recurring) | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 | -1.97 | -0.56 | |
| EPS (Basic, Before Extraordinaries) | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 | -1.97 | -0.56 | |
| EPS (Diluted) | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 | -1.97 | -0.56 | |
| EBITDA | -60 | -30 | -35 | -45 | -47 | -12 | -5 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | |
| Shares Outstanding | 68 | 48 | 27 | 26 | 12 | 12 | 12 | |
| Market Capitalization | 272 | 86 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Brennan Aoife | President and CEO | Jun 29 '26 | Sale | 13.17 | 30,902 | 406,979 | 87,731 | Jun 30 |
| Brennan Aoife | President and CEO | Jun 27 '26 | Option Exercise | 0.00 | 68,750 | 0 | 118,633 | Jun 30 |
| Thomas Stephen Basil | Director | Feb 26 '26 | Sale | 7.01 | 16,313 | 114,289 | 154,657 | Feb 27 |
| Thomas Stephen Basil | Director | Feb 25 '26 | Sale | 7.00 | 33,687 | 235,964 | 170,970 | Feb 27 |
| Thomas Stephen Basil | Director | Feb 13 '26 | Sale | 5.81 | 10,000 | 58,141 | 204,657 | Feb 17 |
| Thomas Stephen Basil | Director | Feb 12 '26 | Sale | 5.23 | 90,000 | 470,988 | 214,657 | Feb 17 |
| RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | Jan 05 '26 | Buy | 3.50 | 7,111 | 24,889 | 3,403,429 | Jan 07 |
| RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | Dec 12 '25 | Buy | 2.86 | 101,462 | 290,181 | 3,396,318 | Dec 15 |
| RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | Dec 11 '25 | Buy | 2.18 | 213,099 | 464,556 | 3,294,856 | Dec 15 |
| Brennan Aoife | President and CEO | Jun 30 '25 | Sale | 1.22 | 20,618 | 25,154 | 48,132 | Jul 01 |
| Brennan Aoife | President and CEO | Jun 27 '25 | Option Exercise | 0.00 | 68,750 | 0 | 68,750 | Jul 01 |
| Thomas Stephen Basil | Director | Jun 27 '25 | Option Exercise | 0.00 | 25,094 | 0 | 204,282 | Jul 01 |
| Pimblett Emily | SVP, Finance & CAO | Jun 20 '25 | Sale | 1.24 | 1,242 | 1,540 | 18,888 | Jun 20 |
| Pimblett Emily | SVP, Finance & CAO | Jun 18 '25 | Option Exercise | 0.00 | 5,000 | 0 | 20,130 | Jun 20 |
| Thomas Stephen Basil | Director | Mar 27 '25 | Option Exercise | 0.00 | 25,093 | 0 | 179,188 | Mar 27 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.